Monoclonal antibodies in development to prevent respiratory syncytial virus (RSV) in children will not only have to satisfy US Food and Drug Administration requirements for product licensure, they will need to secure a recommendation for use from the Centers for Disease Control and Prevention panel that typically vets traditional vaccines.
The Advisory Committee on Immunization Practices’ new maternal/pediatric RSV work group will consider recommendations for use of RSV vaccines and...





